Genomic Health, Inc. (GHDX) Shares Sold by Bank of Montreal Can

Share on StockTwits

Bank of Montreal Can trimmed its stake in Genomic Health, Inc. (NASDAQ:GHDX) by 34.2% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 25,549 shares of the medical research company’s stock after selling 13,305 shares during the period. Bank of Montreal Can’s holdings in Genomic Health were worth $1,645,000 as of its most recent filing with the SEC.

Several other institutional investors also recently added to or reduced their stakes in the company. Copper Rock Capital Partners LLC purchased a new stake in Genomic Health in the 4th quarter valued at $18,630,000. Vanguard Group Inc raised its position in Genomic Health by 18.6% in the 3rd quarter. Vanguard Group Inc now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after purchasing an additional 337,664 shares during the last quarter. Federated Investors Inc. PA raised its position in Genomic Health by 12,387.3% in the 3rd quarter. Federated Investors Inc. PA now owns 199,921 shares of the medical research company’s stock valued at $14,039,000 after purchasing an additional 198,320 shares during the last quarter. Clearbridge Investments LLC purchased a new stake in Genomic Health in the 3rd quarter valued at $12,880,000. Finally, Vanguard Group Inc. raised its position in Genomic Health by 18.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,151,932 shares of the medical research company’s stock valued at $151,109,000 after purchasing an additional 337,664 shares during the last quarter. 90.09% of the stock is currently owned by institutional investors and hedge funds.

Shares of Genomic Health stock opened at $82.01 on Thursday. The firm has a market cap of $2.96 billion, a price-to-earnings ratio of 8,201.00 and a beta of 0.88. Genomic Health, Inc. has a one year low of $30.04 and a one year high of $92.18.

In other news, CEO Kimberly J. Popovits sold 15,000 shares of the company’s stock in a transaction on Friday, November 16th. The shares were sold at an average price of $76.72, for a total transaction of $1,150,800.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Bros. Advisors Lp Baker sold 256,035 shares of the company’s stock in a transaction on Friday, November 30th. The stock was sold at an average price of $78.95, for a total transaction of $20,213,963.25. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 2,257,202 shares of company stock valued at $167,610,659. 45.80% of the stock is owned by insiders.

Several analysts recently commented on GHDX shares. BidaskClub downgraded shares of Genomic Health from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, December 18th. Raymond James initiated coverage on shares of Genomic Health in a research report on Tuesday, October 23rd. They set a “market perform” rating for the company. Zacks Investment Research restated a “hold” rating on shares of Genomic Health in a research report on Tuesday, November 13th. Needham & Company LLC initiated coverage on shares of Genomic Health in a research report on Wednesday, January 2nd. They set a “strong-buy” rating and a $86.00 price objective for the company. Finally, CIBC initiated coverage on shares of Genomic Health in a research report on Wednesday, December 19th. They set a “market perform” rating for the company. Nine investment analysts have rated the stock with a hold rating, one has given a buy rating and three have issued a strong buy rating to the company. Genomic Health has an average rating of “Buy” and an average price target of $58.50.

WARNING: This piece was originally published by Macon Daily and is owned by of Macon Daily. If you are accessing this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The correct version of this piece can be read at https://macondaily.com/2019/02/14/genomic-health-inc-ghdx-shares-sold-by-bank-of-montreal-can.html.

Genomic Health Profile

Genomic Health, Inc, a healthcare company, provides actionable genomic information to personalize cancer treatment decisions worldwide. It develops and commercializes genomic-based clinical laboratory services that analyze the underlying biology of cancer, allowing physicians and patients to make individualized treatment decisions.

Featured Story: Momentum Investing

Want to see what other hedge funds are holding GHDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Genomic Health, Inc. (NASDAQ:GHDX).

Institutional Ownership by Quarter for Genomic Health (NASDAQ:GHDX)

Receive News & Ratings for Genomic Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genomic Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply